China Re Q1 2026: Aggregated Solvency Ratio Holds at 218%, Net Profit Edges Down 5.35%

Bulletin Express
04/29

China Reinsurance (Group) Corporation (“China Re”) has released its unaudited key solvency and operating metrics for the three months ended 31 March 2026.

Solvency Strength • Parent-level core and aggregated solvency adequacy ratios both stood at 218%, comfortably above the 100% regulatory minimum. • Subsidiaries also remained solid: China Re P&C recorded an aggregated ratio of 212%, China Re Life 185%, and China Continent Insurance 277%.

Group-Level Earnings • Consolidated insurance income reached 51.21 billion RMB, down 4.47% from 53.60 billion RMB in Q1 2025. • Consolidated net profit came in at 3.32 billion RMB, a 5.35% year-on-year decline.

Subsidiary Breakdown (January–March 2026) • China Re P&C: insurance income 12.70 billion RMB, net profit 0.85 billion RMB; return on net assets (ROE) 3.16%. • China Re Life: insurance income 15.61 billion RMB, net profit 0.56 billion RMB; ROE 2.29%. • China Continent Insurance: insurance income 16.38 billion RMB, net profit 0.45 billion RMB; combined ratio 99.45%.

Balance-Sheet Snapshot (31 March 2026, parent level) • Total assets: 100.30 billion RMB • Net assets: 63.60 billion RMB • Insurance contract liabilities: 19.37 billion RMB

Investment Performance • Parent-level annualised investment yield registered 0.50%; the combined investment yield (including realised and unrealised gains) was 0.41%. • Three-year average combined investment yield remained at 3.60%.

Operational Efficiency • Parent-level reinsurance combined ratio was 93.00%, with a combined expense ratio of 61.95% and a combined loss ratio of 31.05%. • China Re P&C posted a 97.47% combined ratio, whereas China Re Life recorded 96.97%.

All figures are prepared under PRC accounting standards and have not been audited. Shareholders and investors are advised to refer to the full solvency reports available on the respective company websites and exercise caution when dealing in the shares of China Re.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10